Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies

Minny Bhatty, Shumei Kato, Sarina A. Piha-Paul, Aung Naing, Vivek Subbiah, Helen J. Huang, Daniel D. Karp, Apostolia M. Tsimberidou, Ralph G. Zinner, Wen Jen Hwu, Milind Javle, Sapna P. Patel, Mimi I. Hu, Gauri R. Varadhachary, Anthony P. Conley, Nishma M. Ramzanali, Veronica R. Holley, Razelle Kurzrock, Funda Meric-Bernstam, Young Kwang ChaeKevin B. Kim, Gerald S. Falchook, Filip Janku*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science